Recombinant Human CCL18 protein

中文名： C-C基序趋化因子18(CCL18)重组蛋白
别名： CCL18；AMAC1；DCCK1；MIP4；C-C motif chemokine 18

货号: PA1000-454DB

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	> 95 % SDS-PAGE.
种属	Human
靶点	CCL18
Uniprot No	P55774
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	21-89aa
氨基酸序列	AQVGTNKELCCLVYTSWQIPQKFIVDYSETSPQCPKPGVILLTKRGRQIC ADPNKKWVQKYISDLKLNA
预测分子量	8 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于CCL18重组蛋白的3篇示例参考文献(内容为模拟概括，建议通过学术数据库核实具体文献)：

---

1. **文献名称**: *CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3*

**作者**: Chen J, et al.

**摘要**: 研究揭示了重组CCL18蛋白通过结合受体PITPNM3激活下游信号通路，促进乳腺癌细胞的迁移和侵袭，为靶向肿瘤微环境的治疗提供依据。

2. **文献名称**: *Recombinant CCL18 enhances pulmonary fibrosis through modulation of TGF-β1 signaling*

**作者**: Smith KA, et al.

**摘要**: 通过动物模型证实，外源性重组CCL18蛋白加剧肺纤维化进程，其机制与TGF-β1通路激活及成纤维细胞活化相关，提示CCL18作为纤维化疾病生物标志物的潜力。

3. **文献名称**: *Expression and purification of functional human CCL18 in a prokaryotic system*

**作者**: Li X, et al.

**摘要**: 报道了一种利用大肠杆菌表达系统高效制备具有生物活性的重组人CCL18蛋白的方法，并通过体外趋化实验验证其诱导免疫细胞迁移的功能。

---

建议通过 **PubMed/Google Scholar** 检索关键词“CCL18 recombinant”“CCL18 function”获取真实文献。

背景信息

CCL18 (C-C motif chemokine ligand 18), also known as macrophage inflammatory protein-1γ (MIP-1γ) or AMAC-1. is a small secretory protein belonging to the CC chemokine family. It is constitutively expressed by antigen-presenting cells, particularly macrophages and dendritic cells, under the regulation of cytokines like IL-4. IL-13. and IL-10. CCL18 plays a pivotal role in immune modulation, primarily through its chemotactic activity toward lymphocytes, dendritic cells, and fibroblasts. Its receptor remains partially characterized, with studies suggesting interactions with PITPNM3 (a non-classical G protein-coupled receptor) and potential cross-reactivity with CCR8.

Structurally, human CCL18 consists of 69 amino acids and shares homology with other CC chemokines. Its recombinant form is typically produced using prokaryotic (e.g., E. coli) or eukaryotic expression systems, followed by purification techniques like affinity chromatography. Recombinant CCL18 has become a critical tool for studying pathological mechanisms in fibrotic diseases, cancer, and autoimmune disorders. Notably, elevated CCL18 levels correlate with disease progression in pulmonary fibrosis, liver cirrhosis, and various carcinomas, where it contributes to immunosuppressive microenvironments by recruiting regulatory T cells and promoting alternative macrophage activation.

In cancer research, recombinant CCL18 is investigated for its dual role: facilitating tumor metastasis through extracellular matrix remodeling while simultaneously suppressing anti-tumor immunity. Its clinical potential extends to biomarker applications, with studies exploring its diagnostic value in malignancies and inflammatory conditions. However, challenges persist in fully elucidating its receptor signaling pathways and therapeutic targeting strategies. Current research focuses on developing CCL18-neutralizing antibodies or receptor antagonists as potential treatments for fibrosis and immune-related disorders.